Amylyx Pharmaceuticals (AMLX) Projected to Post Quarterly Earnings on Tuesday

Amylyx Pharmaceuticals (NASDAQ:AMLX) is anticipated to post its Q4 2025 results before the market opens on Tuesday, March 3rd. Analysts expect Amylyx Pharmaceuticals to post earnings of ($0.30) per share and revenue of ($0.0520) million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 8:00 AM ET.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX stock opened at $15.17 on Friday. The stock’s 50-day moving average is $13.73 and its 200 day moving average is $13.03. Amylyx Pharmaceuticals has a 1-year low of $2.60 and a 1-year high of $17.49. The company has a market cap of $1.67 billion, a P/E ratio of -8.43 and a beta of -0.31.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. HC Wainwright raised their price target on shares of Amylyx Pharmaceuticals from $20.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, February 10th. Bank of America increased their target price on shares of Amylyx Pharmaceuticals from $15.00 to $19.00 and gave the company a “buy” rating in a research report on Friday, February 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Monday, December 29th. Finally, Wall Street Zen downgraded Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.63.

Insider Buying and Selling

In related news, CEO Joshua B. Cohen sold 136,193 shares of the stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $13.59, for a total value of $1,850,862.87. Following the transaction, the chief executive officer owned 3,378,621 shares in the company, valued at approximately $45,915,459.39. This represents a 3.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Camille L. Bedrosian sold 6,580 shares of the company’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $14.35, for a total transaction of $94,423.00. Following the completion of the sale, the insider directly owned 175,756 shares in the company, valued at $2,522,098.60. This trade represents a 3.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 157,783 shares of company stock worth $2,122,808 in the last quarter. 12.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Landscape Capital Management L.L.C. raised its stake in shares of Amylyx Pharmaceuticals by 17.5% during the 4th quarter. Landscape Capital Management L.L.C. now owns 12,226 shares of the company’s stock valued at $148,000 after buying an additional 1,825 shares during the last quarter. Meeder Asset Management Inc. acquired a new stake in Amylyx Pharmaceuticals during the fourth quarter worth about $25,000. The Manufacturers Life Insurance Company raised its position in Amylyx Pharmaceuticals by 13.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 26,988 shares of the company’s stock valued at $326,000 after acquiring an additional 3,198 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in Amylyx Pharmaceuticals by 1,116.9% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,454 shares of the company’s stock valued at $54,000 after acquiring an additional 4,088 shares during the period. Finally, California State Teachers Retirement System purchased a new stake in Amylyx Pharmaceuticals in the 2nd quarter worth approximately $28,000. 95.84% of the stock is owned by institutional investors and hedge funds.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.